Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-04-14
2009-10-06
Peng, Bo (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C435S456000, C424S093200
Reexamination Certificate
active
07598078
ABSTRACT:
The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
REFERENCES:
patent: 5922315 (1999-07-01), Roy
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6670188 (2003-12-01), Vogels et al.
patent: 6733993 (2004-05-01), Emini et al.
patent: 6913922 (2005-07-01), Bout et al.
patent: 2003/0044421 (2003-03-01), Emini et al.
patent: 99201545.3 (1999-05-01), None
patent: 0 978 566 (2000-02-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 98/32842 (1998-07-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 99/64582 (1999-12-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/60106 (2000-10-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/21201 (2001-03-01), None
patent: WO 02/22080 (2002-03-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/053759 (2002-07-01), None
patent: WO 2004/028478 (2004-04-01), None
Rodrigues EG et al. “Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria.” J Immunol. Feb 1, 1997;158(3):1268-74.
Natuk et al. “Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees” AIDS Res. Hum. Retrovirus, 1993, vol. 9, No. 5, pp. 395-404.
Tetteh K. et al “Progress and challenges towards the development of malaria vaccines.” Biogruds, 2007;21(6):357-73.
PCT International Search Report, PCT/EP03/50748, dated Sep. 27, 2004.
PCT International Preliminary Examination Report, PCT/EP03/50748, dated Feb. 14, 2005.
Mack et al., “Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype,” Human Gene Therapy, 1997, pp. 99-109, vol. 8, No. I.
Mastrangeli et al., “‘Sero-Switch’ Adenovirus-Mediated in Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype,” Human Gene Therapy, 1996. pp. 79-87, vol. 7, No. 1.
Parks et al., “Use of a helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration,” Gene Therapy, Sep. 1999, pp. 1565-1573, vol. 6, No. I.
Moffatt et al., “Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non- Human Adenoviruses: Implications in Gene Therapy,” Virology, Jun. 30, 2000, pp. 159-167, vol. 272, No. 1.
Lubeck et al., “Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus,” Proc. Natl. Acad. Sci. USA, 1989, pp. 6763-6767, vol. 86, No. 17.
Natuk et al., “Immunogenicity of Recombinant Human Adenovims—Human Immunodeficiency Virus Vaccines in Chimpanzees,” AIDS Research and Human Retroviruses, 1993, pp. 395-404, vol. 9, No. 5.
Natuk et al., “Adenovirus—human deficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model,” Proc. Natl. Acad. Sci. USA, Aug. 1992, pp. 7777-7781, vol. 89, No. 16.
Hsu et al., “Immunogenicity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenvirus Types 4, 5, and 7 Vectors in Dogs and a chimpanzee,” Journal of Infectious Diseases, Oct. 1, 1992, pp. 769-775, vol. 166, No. 4.
Kass-Eisler et al., “Circumventing the immune response to adenovirus-mediated gene therapy,” Gene Therapy, Feb. 1, 1996, pp. 154-162, vol. 2, No. 3.
Natuk et al., “Adenovirus Vectored Vaccines,” Developments in Biological Standardization, 1994, pp. 71-77, vol. 82.
Roy et al., “Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875- 6879, vol. 72, No. 8.
Sullivan et al., “Development of a preventive vaccine for Ebola virus infection in primates,” Nature, 2000, pp. 605-609, vol. 408, No. 6812.
Shiver et al., “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity,” Nature, 2002, pp. 331-335, vol. 415, No. 6869.
Basler et al., “Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35,” Gene, 1996, pp. 249-254, vol. 170.
Flomenberg et al., “Molecular Epidemiology of Adenovirus Type 35 Infections in lmmunocompromised Hosts,” The Journal of Infectious Diseases, Jun. 1987, pp. 1127-1134, vol. 155, No. 6.
Flomenberg et al., “Sequence and genetic Organization of Adenovirus Type 35 Early Region 3,” Journal of Virology, Nov. 1988, pp. 4431-4437, vol. 62, No. II.
Gahery-Segard et al., “Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti- Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity,” Journal of Virology, Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Kang et al., “Molecular Cloning and Physical Mapping of the DNA of Human Adenovirus Type 35,” Acta Microbiologica Hungarica, 1999, pp. 67-75, vol. 36, No. l.
Krasnykh et al., “Generation of Recombinant Adenovirus Vectors with modified Fibers for Altering Viral Tropism,” Journal of Virology, Oct. 1996, pp. 6839-3846, vol. 70, No. 10.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Rosenfeld et al., Adenovirus-Mediated Transfer of a recombinant alpha-l-Antitrypsin Gene to the Lung Epithelium in Vivo, Science, Apr. 19, 1991, pp. 431-434, vol. 252.
Stevenson et al., “Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain,” Journal of Virology, May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet et al., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,” Human Gene Therapy, 1990, pp. 241-256, vol. I.
European Search Report, EP 03 78 0172, dated Dec. 6, 2007.
Bostic et al., Quantitative Analysis of Neutralizing Immune Response to Human Parvovirus B19 Using a Novel Reverse Transcriptase-Polymerase Chain Reaction-Based Assay, Journal of Infectious Diseases, 1999, pp. 619-626, vol. 179, Chicago, IL, US.
Klein et al., Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR, Gene Therapy, 2000, pp. 458-463, vol. 7.
Nishimura et al., Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, Mar. 2002, pp. 2123-2130, vol. 76, No. 5.
Schroter et al., Quantitative Detection of Hepatitis C Virus RNA by Light Cycler PCR and Comparison with Two Different PCR Assays, Journal of Clinical Microbiology, Feb. 2001, pp. 765-768, vol. 39, No. 2.
Spenlehauer et al., A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1, Virology, 2001, pp. 292-300, vol. 280.
Sprangers et al., Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors, Journal of Clinical Microbiology, Nov. 2003, pp. 5046-5052, vol. 41, No. 11.
Vogels et al., Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity, Journal of Virology. Aug. 2003, pp. 8263-8271, vol. 7
Havenga Menzo Jans
Holterman Lennart
Kostense Stefan
Pau Maria Grazia
Sprangers Mieke C.
Crucell Holland B.V.
Peng Bo
TraskBritt P.C.
LandOfFree
Settings for recombinant adenoviral-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Settings for recombinant adenoviral-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Settings for recombinant adenoviral-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4101322